Cancer NetworkOriginal article
<![CDATA[Eftilagimod Alfa Combo Shows Positive Overall Survival in Advanced NSCLC]]>
Data ReadoutpositiveEftilagimod AlfaPositive
AI Analysis
Summary
Eftilagimod Alfa combination therapy demonstrated positive mature overall survival data in the INSIGHT-003 trial for advanced NSCLC, with results comparing favorably to historical benchmarks in frontline treatment.
Clinical Trial Data
Primary Endpoint
Met
NCT ID
Outcome Details
Mature overall survival data from INSIGHT-003 trial compare favorably with historical benchmarks in frontline NSCLC therapy
Importance:7/10
Sentiment:
0.75
NSCLCOncologyOverall SurvivalPhase 3Frontline TherapyImmunotherapy
Read the original article
Published by Cancer Network on July 14, 2026 2:45 PM